BlackRock
MIRM icon

BlackRock’s Mirum Pharmaceuticals MIRM Stock Holding History

BlackRock’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355M Buy
3,846,530
+201,244
+6% +$18.9M 0.01% 1327
2025
Q4 		$288M Buy
3,645,286
+42,852
+1% +$3.08M ﹤0.01% 1460
2025
Q3 		$264M Buy
3,602,434
+25,343
+0.7% +$1.61M ﹤0.01% 1499
2025
Q2 		$182M Buy
3,577,091
+237,534
+7% +$10.6M ﹤0.01% 1676
2025
Q1 		$150M Sell
3,339,557
-95,071
-3% -$4.48M ﹤0.01% 1751
2024
Q4 		$142M Buy
3,434,628
+66,471
+2% +$2.77M ﹤0.01% 1867
2024
Q3 		$131M Buy
3,368,157
+130,108
+4% +$5.19M ﹤0.01% 1924
2024
Q2 		$111M Buy
3,238,049
+785,776
+32% +$20.6M ﹤0.01% 1963
2024
Q1 		$61.6M Sell
2,452,273
-9,477
-0.4% -$261K ﹤0.01% 2320
2023
Q4 		$72.7M Buy
2,461,750
+348,341
+16% +$10.5M ﹤0.01% 2267
2023
Q3 		$66.8M Buy
2,113,409
+83,034
+4% +$2.27M ﹤0.01% 2231
2023
Q2 		$52.5M Buy
2,030,375
+320,549
+19% +$8.53M ﹤0.01% 2450
2023
Q1 		$41.1M Sell
1,709,826
-426,851
-20% -$9.73M ﹤0.01% 2582
2022
Q4 		$41.7M Buy
2,136,677
+387,328
+22% +$7.66M ﹤0.01% 2591
2022
Q3 		$36.8M Buy
1,749,349
+353,337
+25% +$8.51M ﹤0.01% 2678
2022
Q2 		$27.2M Buy
1,396,012
+613,182
+78% +$14.5M ﹤0.01% 2911
2022
Q1 		$17.2M Buy
782,830
+10,732
+1% +$219K ﹤0.01% 3268
2021
Q4 		$12.3M Buy
772,098
+161,533
+26% +$2.51M ﹤0.01% 3549
2021
Q3 		$12.2M Buy
610,565
+2,831
+0.5% +$46K ﹤0.01% 3586
2021
Q2 		$10.5M Sell
607,734
-153,105
-20% -$2.74M ﹤0.01% 3621
2021
Q1 		$15.1M Buy
760,839
+205,950
+37% +$3.94M ﹤0.01% 3339
2020
Q4 		$9.69M Buy
554,889
+132,920
+31% +$2.61M ﹤0.01% 3378
2020
Q3 		$8.13M Sell
421,969
-3,569
-0.8% -$76.6K ﹤0.01% 3339
2020
Q2 		$8.28M Buy
425,538
+168,803
+66% +$2.82M ﹤0.01% 3291
2020
Q1 		$3.59M Buy
256,735
+75,566
+42% +$1.24M ﹤0.01% 3475
2019
Q4 		$4.44M Buy
181,169
+146,114
+417% +$1.56M ﹤0.01% 3542
2019
Q3 		$352K Buy
+35,055
New +$430K ﹤0.01% 4231

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock's MIRM Position: Q1 2026 in Review

BlackRock increased its Mirum Pharmaceuticals (MIRM) stake by 5.5% in Q1 2026, buying an estimated $18.9M and bringing the position to 3,846,530 shares worth $355M. The position accounts for 0.01% of the portfolio, ranked #1327.

BlackRock first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • BlackRock held 3,846,530 shares of Mirum Pharmaceuticals worth $355M as of Q1 2026.
  • BlackRock bought 201,244 Mirum Pharmaceuticals shares in Q1 2026, an estimated $18.9M.
  • Mirum Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q1 2026, its #1327 holding.
  • BlackRock first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.